<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03053466</url>
  </required_header>
  <id_info>
    <org_study_id>CBT-501-01</org_study_id>
    <nct_id>NCT03053466</nct_id>
  </id_info>
  <brief_title>CBT-501 Study for Select Advanced or Relapsed/Recurrent Solid Tumors</brief_title>
  <official_title>A Phase 1 Multicenter, Dose Escalation Study of CBT-501 in Subjects With Select Advanced or Relapsed/Recurrent Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>CBT Pharmaceuticals (Australia) Pty Ltd</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Novotech (Australia) Pty Limited</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>CBT Pharmaceuticals (Australia) Pty Ltd</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine the safety, tolerability, and recommended dose of
      CBT-501 in individuals with advanced or relapsed or recurrent solid tumors.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a Phase 1, multicenter, 2-part study with a Dose-Escalation Segment and Dose and
      Disease Expansion Cohort of CBT-501 injection, a humanized IgG4 monoclonal antibody,
      targeting the Programmed Death-1 (PD-1) membrane receptor on T lymphocytes and other cells of
      the immune system. Select advanced solid tumor malignancies will receive escalating doses of
      CBT-501.

      Dose escalation will occur in three subject cohorts until a protocol defined dose limited
      toxicity (DLT) occurs, not due to disease progression or inter-current illness, and a
      tentative maximum tolerated dose (MTD) is determined.

      At the tentative MTD or recommended Phase 2 dose (RP2D), at least two tumor types will be
      assessed to further evaluate toxicity and preliminary efficacy.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">March 27, 2017</start_date>
  <completion_date type="Anticipated">March 2019</completion_date>
  <primary_completion_date type="Anticipated">February 2018</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
    <masking_description>Open Label</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Number of participants with treatment related adverse events as assessed by Common Terminology Criteria for Adverse Events (CTCAE v4.03) in patients with advance solid tumors</measure>
    <time_frame>From the time of informed consent from signature until Day 28 after Cycle 1; Dose Escalation - Approximately 9 months</time_frame>
    <description>Adverse events, serious adverse events, dose limiting toxicities according to the National Cancer Institute (NCI) Terminology Criteria for Adverse Events (CTCAE v4.03)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Determine the recommended Phase 2 dose and schedule</measure>
    <time_frame>An average of 1 year</time_frame>
    <description>adverse events, serious adverse events, dose limiting toxicities</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the plasma concentration versus time curve (AUC)</measure>
    <time_frame>Up to 4 months (1 cycle = 28 days)</time_frame>
    <description>AUC, 0-infinity</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum plasma concentration</measure>
    <time_frame>Up to 4 months (1 cycle = 28 days)</time_frame>
    <description>Cmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to reach Cmax</measure>
    <time_frame>Up to 4 months (1 cycle = 28 days)</time_frame>
    <description>Tmax</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Objective Response Rate</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Antitumor activity per RECIST v1.1 and by irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Antitumor activity per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Response</measure>
    <time_frame>Approximately 12 months</time_frame>
    <description>Antitumor activity per irRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease Control Rate</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Antitumor activity per RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>Approximately 24 months</time_frame>
    <description>Antitumor activity per RECIST v1.1 and per irRECIST, deaths from any cause</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Correlation of tumor-infiltrating lymphocyte counts at baseline and post administration of CBT-501</measure>
    <time_frame>Approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Correlation of PD-1 and PD-L1 expression at baseline to clinical response</measure>
    <time_frame>Approximately 24 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>PD-1 receptor occupancy of CBT-501</measure>
    <time_frame>Up to 6 months</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Degree of immunogenicity of CBT-501</measure>
    <time_frame>Approximately 24 months</time_frame>
  </other_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Advanced Cancer</condition>
  <condition>ColoRectal Cancer</condition>
  <condition>Endometrial Cancer</condition>
  <condition>Gastric Cancer</condition>
  <condition>Hepatocellular Cancer</condition>
  <condition>Nonsmall Cell Lung Cancer</condition>
  <condition>Mesothelioma</condition>
  <condition>Ovarian Cancer</condition>
  <condition>Renal Cancer</condition>
  <condition>Nasopharyngeal Cancer</condition>
  <condition>Esophageal Cancer</condition>
  <condition>Gastroesophageal Junction Adenocarcinoma</condition>
  <arm_group>
    <arm_group_label>Single-Arm</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>CBT-501</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CBT-501</intervention_name>
    <description>Subjects will be assigned to a dose level in the order of study entry. Treatment includes a minimum of four 28-day cycles at three planned dose levels (1, 3, and 10 mg/kg). Each treatment cycle is comprised of 2 doses of study drug administered by IV infusion on Days 1, 15 on a 28-day cycle.</description>
    <arm_group_label>Single-Arm</arm_group_label>
    <other_name>GB226</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major Inclusion Criteria:

          -  Able to understand and comply with study procedures, understand the risks involved,
             and provide written informed consent

          -  Histologically and / or cytological confirmed solid tumors: colorectal, endometrial,
             gastric including, gastroesophageal junction adenocarcinoma (GC), head and neck
             (esophageal, nasopharyngeal), hepatocellular (HCC), non-small cell lung cancer,
             mesothelioma, ovarian, and renal cell carcinoma (RCC), either refractory or relapsed
             to standard therapy or for which no effective standard therapy is available.

          -  No restriction to number of prior therapies for Dose Escalation Segment

          -  Receive no more than three systemic prior therapies for Dose and Disease Expansion
             Cohorts

          -  Tumor biopsy at study entry and during therapy

          -  Measurable disease according to RECIST v1.1

        Major Exclusion Criteria:

          -  History of severe hypersensitivity to mAbs, excipients of the drug product or other
             components

          -  Prior malignancy active within the previous 2 years except for locally curable cancers
             that have been cured, such as basal or squamous cell skin cancer, superficial bladder
             cancer or carcinoma in situ of the cervix or breast

          -  Any active autoimmune disease or a documented history of autoimmune disease, or
             history of syndrome that required systemic steroids or immunosuppressive medications,
             except for subjects with vitiligo or resolved childhood asthma/atopy

          -  Prior therapy with an anti-PD-1, anti-PD-L1, anti-PDL-2, or anti-CTLA-4 antibody (or
             any other antibody targeting T cell co-stimulation pathways) (except NSCLC)

          -  Symptomatic primary tumors or metastasis of brain and/or central nervous system,
             uncontrolled with antiepileptic and requiring high doses of steroids
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gavin Choy, PharmD, MBA</last_name>
    <role>Study Director</role>
    <affiliation>EVP and Chief Operating Officer, CBT Pharmaceuticals, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Purvi Patel, MS</last_name>
    <phone>(925) 272-4090</phone>
    <email>purvi.patel@cbtpharma.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Gavin Choy, PharmD, MBA</last_name>
    <phone>(925) 272-4090</phone>
    <email>gavin.choy@cbtpharma.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Chris O'Brien Lifehouse</name>
      <address>
        <city>Camperdown</city>
        <state>New South Wales</state>
        <zip>2050</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacquie Harvey</last_name>
      <phone>+61 2 8514 0194</phone>
      <email>Jacquie.Harvey@lh.org.au</email>
    </contact>
    <contact_backup>
      <last_name>Catriona McNeil, MBBS</last_name>
      <phone>+61 2 8514 0144</phone>
      <email>catriona.mcneil@lh.org.au</email>
    </contact_backup>
    <investigator>
      <last_name>Catriona McNeil, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Cabrini Education and Research Precinct</name>
      <address>
        <city>Malvern</city>
        <state>Victoria</state>
        <zip>3144</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nina Box</last_name>
      <phone>+61 (0)3 9508 3421</phone>
      <email>n.box@cabrini.co.au</email>
    </contact>
    <contact_backup>
      <last_name>Kate Hurford</last_name>
      <phone>+61 (0) 3 9508 3411</phone>
      <email>KHurford@cabrini.com.au</email>
    </contact_backup>
    <investigator>
      <last_name>Gary Richardson, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Nucleus Network</name>
      <address>
        <city>Melbourne</city>
        <state>Victoria</state>
        <zip>3004</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Stefanie Hartley</last_name>
      <phone>+61 3 9076 9020</phone>
      <email>s.hartley@nucleusnetwork.com.au</email>
    </contact>
    <investigator>
      <last_name>Mark Voskoboynik, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Linear Clinical Research</name>
      <address>
        <city>Nedlands</city>
        <state>Western Australia</state>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Zelda Herbst</last_name>
      <phone>+61 (0) 8 6382 5113</phone>
      <email>zherbst@linear.org.au</email>
    </contact>
    <investigator>
      <last_name>Michael Millward, MBBS</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <link>
    <url>http://www.cbtpharma.com</url>
    <description>Company website for CBT Pharmaceuticals, Inc.</description>
  </link>
  <verification_date>February 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 30, 2017</study_first_submitted>
  <study_first_submitted_qc>February 12, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">February 15, 2017</study_first_posted>
  <last_update_submitted>February 7, 2018</last_update_submitted>
  <last_update_submitted_qc>February 7, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">February 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Advanced Solid Tumor</keyword>
  <keyword>Relapsed Solid Tumor</keyword>
  <keyword>Recurrent Solid Tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
    <mesh_term>Colorectal Neoplasms</mesh_term>
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Stomach Neoplasms</mesh_term>
    <mesh_term>Esophageal Neoplasms</mesh_term>
    <mesh_term>Mesothelioma</mesh_term>
    <mesh_term>Endometrial Neoplasms</mesh_term>
    <mesh_term>Kidney Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Renal Cell</mesh_term>
    <mesh_term>Nasopharyngeal Neoplasms</mesh_term>
    <mesh_term>Liver Neoplasms</mesh_term>
    <mesh_term>Carcinoma, Non-Small-Cell Lung</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

